Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
West China Hospital, The Research Units of West China (2018RU012)-Chinese Academy of Medical Sciences, Sichuan University, Chengdu, China.
Sci Rep. 2024 Oct 14;14(1):23999. doi: 10.1038/s41598-024-74791-w.
It is currently unclear whether there is a connection between Life's Essential 8 (LE8) and cardiovascular disease (CVD), as well as mortality in people with nonalcoholic fatty liver disease (NAFLD). Our goal was to explore these relationships by examining data collected in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2018. We identified eligible participants with NAFLD based on NHANES 2005-2018 data. CVD status was acquired through self-reported information, and using the National Death Index, mortality data were prospectively matched. The diagnosis of NAFLD relied on noninvasive biomarkers. The research involved 9094 individuals who were identified as having NAFLD, with a mean age of 52.05 years. Each incremental LE8 score exhibited a significant association, leading to a 3%, 3%, 4%, 3%, 3%, 4%, and 4% reduction in the odds of experiencing CVD, ischemic heart disease, congestive heart failure, coronary heart disease, heart attack, angina, and stroke in individuals with NAFLD. A strong correlation was found between maintaining a superior level of Cardiovascular Health (CVH), as shown by a LE8 score ranging from 80 to 100, and a reduced occurrence of CVD and its various forms in NAFLD (all p for trend < 0.0001). Likewise, LE8 demonstrated protective benefits on mortality in NAFLD, showing that following a high CVH (in contrast to low CVH) was linked to reductions of 64%, 71%, and 74% in all-cause, CVD, and cancer mortality, respectively. Restricted cubic spline analyses suggested noteworthy dose-response relationships between LE8 and CVD, specifically its types in NAFLD, and a nonlinear correlation with CVD mortality. Interaction analyses highlighted age and race as significant effect modifiers. CVH, as evaluated by LE8, demonstrated an independent association with decreased odds of CVD and mortality risk in individuals with NAFLD. Our findings substantiate that adhering to LE8 may alleviate the excessive burden of CVD and mortality in the context of NAFLD.
目前尚不清楚 Life's essential 8（LE8）与非酒精性脂肪性肝病（NAFLD）患者的心血管疾病（CVD）和死亡率之间是否存在关联。我们的目标是通过检查 2005 年至 2018 年期间在美国国家健康和营养检查调查（NHANES）中收集的数据来探讨这些关系。我们根据 NHANES 2005-2018 年的数据确定了符合条件的 NAFLD 参与者。CVD 状况通过自我报告的信息获得，使用国家死亡指数对死亡率数据进行前瞻性匹配。NAFLD 的诊断依赖于非侵入性生物标志物。该研究涉及 9094 名被诊断为 NAFLD 的个体，平均年龄为 52.05 岁。每个递增的 LE8 评分都与 CVD、缺血性心脏病、充血性心力衰竭、冠心病、心脏病发作、心绞痛和中风的风险降低 3%、3%、4%、3%、3%、4%和 4%显著相关。在 NAFLD 患者中，保持较高的心血管健康（CVH）水平（LE8 评分范围为 80 至 100）与 CVD 及其各种形式的发生呈显著负相关（所有趋势检验 P 值均<0.0001）。同样，LE8 对 NAFLD 患者的死亡率也有保护作用，表明高 CVH（与低 CVH 相比）与全因、CVD 和癌症死亡率分别降低 64%、71%和 74%相关。限制性立方样条分析表明，LE8 与 CVD 及其在 NAFLD 中的各类型之间存在显著的剂量反应关系，并且与 CVD 死亡率呈非线性相关。交互分析突出了年龄和种族作为重要的效应修饰因子。LE8 评估的 CVH 与 NAFLD 患者 CVD 发病风险和死亡率的降低呈独立相关。我们的研究结果证实，在 NAFLD 背景下，遵循 LE8 可能会减轻 CVD 和死亡率的过度负担。
